Skip to main content
Right Decisions for Health and Care
Right Decisions for Health and Care
Search for toolkits, guidelines and other information:
Search 'Polypharmacy guidance: realistic prescribing'...
Menu
All resources
Organisations
Learning & support
How to deliver RDS tools
Feedback
Right Decisions
Polypharmacy guidance: realistic prescribing
Efficacy (NNT)
Back
By Condition
Heart Failure
Announcements and latest updates
test announcement
Print this page
Heart Failure
Polypharmacy guidance: realistic prescribing
Scottish Government Effective Prescribing & Therapeutics Division
ACE inhibitor (Enalapril 2.5-40mg/day (uptitrated as tolerated) vs placebo, severe heart failure
ACE inhibitor (Enalapril 2.5 - 20mg/day (uptitrated as tolerated) vs placebo, heart failure
ACE inhibitor (Enalapril 2.5 - 20mg/day (uptitrated as tolerated) vs placebo, CKD
ACE inhibitor and Indapmide (perindopril 4mg/day and Idapamide 2.5mg/day) vs placebo
ACE inhibitor (Ramipril 10mg/day) vs Placebo (High-risk of cardiovascular disease without LVSD or heart failure)
ACE inhibitor (Enalapril 2.5 - 40mg/day (uptitrated as tolerated) vs placebo, asymptomatic heart failure
Angiotensin II receptor antagonist (Telmistartan 80mg/day) vs placebo
Angiotensin II receptor blocker (Candesartan 4-32mg/day)
Betablocker (Bisoprolol titrated to target dose of 10mg/day) vs placebo
Betablocker (Carvedilol titrated to target dose of 25mg twice daily) vs placebo
Betablocker (Metoprolol modified release titrated to a target dose of 200mg /day) vs placebo
Betablocker (Nebivolol titrated to a target dose of 10mg/day) vs placebo
Spironolactone 25mg daily vs placebo
Back to the top
Polypharmacy guidance: realistic prescribing
